Skip to content

EFFECTIVENESS OF 3% VS 7% HYPERTONIC SALINE NEBULISATION IN ACUTE BRONCHIOLITIS IN CHILDREN

EFFECTIVENESS OF 3% VS 7% HYPERTONIC SALINE NEBULISATION IN ACUTE BRONCHIOLITIS IN CHILDREN- A RANDOMISED CONTROLLED TRIAL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/01/048643
Enrollment
80
Registered
2023-01-02
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J219- Acute bronchiolitis, unspecified

Interventions

Intervention1: 7%Hypertonic saline: 4ml of 7% nebulized HS with tight-fitting face mask will be given.The nebulisation will be given either by the investigator or by trained staffs with 8-10 litres of

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children from 2 months to 2 years clinically diagnosed with acute bronchiolitis will be included in the study

Exclusion criteria

Exclusion criteria: Children with Chronic cardiopulmonary disease viz. congenital heart disease, cystic lung disease, etc Preterm birth or history of mechanical ventilation in the neonatal period Infants who received bronchodilators within two hours of presentation Children with Family history of asthma Infants who received oral or inhaled corticosteroids during the preceding 2 weeks

Design outcomes

Primary

MeasureTime frame
Length of Hospital Stay (LHS) and improvement in the modified bronchiolitis scoreTimepoint: Modified bronchiolitis score will be assessed at regular intervals of time . Length of hospital stay varies from patient to patient

Secondary

MeasureTime frame
need and duration of supplemental oxygen occurrence of adverse eventsTimepoint: Need for supplemental oxygen will be assessed during the course of stay . Any adverse effects occuring during the course of stay will be monitored and documented and appropriate treatment will be given .

Countries

India

Contacts

Public ContactDrSujatha Sridharan

Chettinad hospital and research institute

sridharansujatha@gmail.com9282176464

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026